Search

Your search keyword '"Rosati, Gerardo"' showing total 12 results
Start Over Author "Rosati, Gerardo" Publisher elsevier bv
12 results on '"Rosati, Gerardo"'

1. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study

Author

Rosati, Gerardo, primary, Corsi, Domenico, additional, Avallone, Antonio, additional, Brugnatelli, Silvia, additional, Dell'Aquila, Emanuela, additional, Cinausero, Marika, additional, Aprile, Giuseppe, additional, Cicero, Giuseppe, additional, Carlomagno, Chiara, additional, Colombo, Alfredo, additional, Rapisardi, Stefania, additional, Pinto, Carmine, additional, Reggiardo, Giorgio, additional, and Bilancia, Domenico, additional

Published
2022
Full Text
View/download PDF

2. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Author

Rosati, Gerardo, primary, Lonardi, Sara, additional, Galli, Fabio, additional, Di Bartolomeo, Maria, additional, Ronzoni, Monica, additional, Zampino, Maria G., additional, Banzi, Maria, additional, Zaniboni, Alberto, additional, Pasini, Felice, additional, Bozzarelli, Silvia, additional, Garattini, Silvio K., additional, Ferrari, Daris, additional, Montesarchio, Vincenzo, additional, Mambrini, Andrea, additional, Ciuffreda, Libero, additional, Galli, Francesca, additional, Pusceddu, Valeria, additional, Carlomagno, Chiara, additional, Bidoli, Paolo, additional, Amoroso, Domenico, additional, Bochicchio, Anna M., additional, Frassineti, Luca, additional, Corsi, Domenico, additional, Bilancia, Domenico, additional, Pastorino, Alessandro, additional, De Stefano, Alfonso, additional, Labianca, Roberto, additional, Bilancia, D., additional, Rosati, G., additional, Montesarchio, V., additional, Iaffaioli, R.V., additional, Nasti, G., additional, Daniele, B., additional, Zagonel, V., additional, Lonardi, S., additional, Pella, N., additional, Aprile, G., additional, Pasini, F., additional, Marchetti, Roma P., additional, Romiti, A., additional, Ciuffreda, L., additional, Ferrari, D., additional, Foa, P., additional, Zaniboni, A., additional, Labianca, R., additional, Mosconi, S., additional, Sobrero, A., additional, Bidoli, P., additional, Cazzaniga, M., additional, Beretta, G.D., additional, Corsi, D.C., additional, Cortesi, E., additional, Barni, S., additional, Petrelli, F., additional, Allione, P., additional, D'Arco, A.M., additional, Valmadre, G., additional, Piazza, E., additional, Veltri, E., additional, Ramus, G. Vietti, additional, Giustini, L., additional, Tumulo, S., additional, Cascinu, S., additional, Granetto, C., additional, Testore, F., additional, Giordano, M., additional, Moroni, M., additional, Di Seri, M., additional, Nuzzo, A., additional, Angelelli, L., additional, Gori, S., additional, Farina, G., additional, Aglietta, M., additional, Franchi, R., additional, Comandé, M., additional, Giordani, P., additional, Tonini, G., additional, Bucci, E., additional, Ballestrero, A., additional, Benasso, M., additional, Graiff, C., additional, Bravi, S., additional, Caffo, O., additional, Silva, R.R., additional, Frontini, L., additional, Rota, S., additional, Cozzi, L., additional, Cantore, M., additional, Maiello, E., additional, Cinieri, S., additional, Silvestris, N., additional, Romito, S., additional, Gebbia, V., additional, Banzi, M., additional, Santoro, A., additional, Artioli, F., additional, Mattioli, R., additional, Contu, A., additional, Di Costanzo, F., additional, Leonardi, F., additional, Cavanna, L., additional, Passalacqua, R., additional, Amoroso, D., additional, Sozzi, P., additional, D'Amico, M., additional, Amadori, D., additional, Frassineti, L., additional, Turci, D., additional, Ravaioli, A., additional, Pasquini, E., additional, Gambi, A., additional, Faedi, M., additional, Cruciani, G., additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Gianni, L., additional, Ronzoni, M., additional, Ionta, M.T., additional, Massidda, B., additional, Scartozzi, M., additional, Zampino, M.G., additional, Bochicchio, A.M., additional, Ciarlo, A., additional, Di Leo, A., additional, Frustaci, S., additional, Rangoni, G., additional, Arizzoia, A., additional, Pavesi, L., additional, Verusio, C., additional, Pinotti, G., additional, Iop, A., additional, De Placido, S., additional, Carlomagno, C., additional, Adamo, V., additional, Ficorella, C., additional, Natale, D., additional, Greco, E., additional, Rulli, E., additional, Galli, F., additional, Poli, D., additional, Porcu, L., additional, and Torri, V., additional

Published
2021
Full Text
View/download PDF

3. Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial

Author

Piccirillo, Maria Carmela, primary, Avallone, Antonio, additional, Carlomagno, Chiara, additional, Maiello, Evaristo, additional, Rosati, Gerardo, additional, Alabiso, Oscar, additional, Nasti, Guglielmo, additional, De Placido, Sabino, additional, Latiano, Tizana Pia, additional, Bilancia, Domenico, additional, Ottaiano, Alessandro, additional, De Stefano, Alfonso, additional, Romano, Carmela, additional, Silvestro, Lucrezia, additional, Nappi, Anna, additional, Cassata, Antonino, additional, Giordano, Pasqualina, additional, Iaffaioli, Rosario Vincenzo, additional, Normanno, Nicola, additional, Perrone, Francesco, additional, and Daniele, Bruno, additional

Published
2020
Full Text
View/download PDF

4. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study

Author

Fanotto, Valentina, primary, Fornaro, Lorenzo, additional, Bordonaro, Roberto, additional, Rosati, Gerardo, additional, Rimassa, Lorenza, additional, Di Donato, Samantha, additional, Santini, Daniele, additional, Tomasello, Gianluca, additional, Leone, Francesco, additional, Silvestris, Nicola, additional, Stragliotto, Silvia, additional, Scartozzi, Mario, additional, Giampieri, Riccardo, additional, Nichetti, Federico, additional, Antonuzzo, Lorenzo, additional, Cinieri, Saverio, additional, Avallone, Antonio, additional, Pellegrino, Antonio, additional, Melisi, Davide, additional, Vasile, Enrico, additional, Gerratana, Lorenzo, additional, and Aprile, Giuseppe, additional

Published
2019
Full Text
View/download PDF

5. Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study

Author

Rosati, Gerardo, primary, Pinto, Carmine, additional, Di Fabio, Francesca, additional, Chiara, Silvana, additional, Lolli, Ivan R., additional, Ruggeri, Enzo M., additional, Ciuffreda, Libero, additional, Ferrara, Raimondo, additional, Antonuzzo, Lorenzo, additional, Adua, Daniela, additional, Racca, Patrizia, additional, Bilancia, Domenico, additional, Benincasa, Elena, additional, Stroppolo, Maria Elena, additional, and Di Costanzo, Francesco, additional

Published
2018
Full Text
View/download PDF

6. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

Author

Cascinu, Stefano, primary, Rosati, Gerardo, additional, Nasti, Guglielmo, additional, Lonardi, Sara, additional, Zaniboni, Alberto, additional, Marchetti, Paolo, additional, Leone, Francesco, additional, Bilancia, Domenico, additional, Iaffaioli, Rosario Vincenzo, additional, Zagonel, Vittorina, additional, Giordano, Monica, additional, Corsi, Domenico C., additional, Ferraú, Francesco, additional, Labianca, Roberto, additional, Ronzoni, Monica, additional, Scartozzi, Mario, additional, Galli, Francesca, additional, Cascinu, Stefano, additional, Romiti, Adriana, additional, Aglietta, Massimo, additional, Mosconi, Stefania, additional, Gianni, Luca, additional, Rulli, Eliana, additional, Poli, Davide, additional, Torri, Valter, additional, De Simone, Irene, additional, Galli, Fabio, additional, Pasini, Felice, additional, Rangoni, Giovanni, additional, Venezia, Raffaele, additional, Sozzi, Pietro, additional, Nuzzo, Antonio, additional, Berardi, Rossana, additional, Frontini, Luciano, additional, Rota, Silvia, additional, and Cozzi, Lorena, additional

Published
2017
Full Text
View/download PDF

7. Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.

Author

Fanotto, Valentina, primary, Uccello, Mario, additional, Pecora, Irene, additional, Rimassa, Lorenza, additional, Leone, Francesco, additional, Rosati, Gerardo, additional, Santini, Daniele, additional, Giampieri, Riccardo, additional, Di Donato, Samantha, additional, Tomasello, Gianluca, additional, Silvestris, Nicola, additional, Pietrantonio, Filippo, additional, Battaglin, Francesca, additional, Avallone, Antonio, additional, Scartozzi, Mario, additional, Lutrino, Stefania, additional, Melisi, Davide, additional, Antonuzzo, Lorenzo, additional, Pellegrino, Antonio, additional, and Aprile, Giuseppe, additional

Published
2017
Full Text
View/download PDF

12. Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study

Author

Emanuela Dell'Aquila, Chiara Carlomagno, Carmine Pinto, Giorgio Reggiardo, Domenico Corsi, Alfredo Colombo, Gerardo Rosati, Giuseppe Cicero, Domenico Bilancia, Antonio Avallone, Giuseppe Aprile, Stefania Rapisardi, Marika Cinausero, Silvia Brugnatelli, Rosati, Gerardo, Corsi, Domenico, Avallone, Antonio, Brugnatelli, Silvia, Dell'Aquila, Emanuela, Cinausero, Marika, Aprile, Giuseppe, Cicero, Giuseppe, Carlomagno, Chiara, Colombo, Alfredo, Rapisardi, Stefania, Pinto, Carmine, Reggiardo, Giorgio, Bilancia, Domenico, and Gerardo Rosati, Domenico Corsi, Antonio Avallone, Silvia Brugnatelli, Emanuela Dell'Aquila, Marika Cinausero, Giuseppe Aprile, Giuseppe Cicero, Chiara Carlomagno, Alfredo Colombo, Stefania Rapisardi, Carmine Pinto, Giorgio Reggiardo, Domenico Bilancia

Subjects
medicine.medical_specialty, Reduced dose, Colorectal cancer, Leucovorin, Cetuximab, Neutropenia, Gastroenterology, FOLFOX, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Panitumumab, Doublet chemotherapy, Anti-EGFR, Aged, Metastatic colorectal cancer, Rectal Neoplasms, business.industry, Anti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patients, Exanthema, medicine.disease, Rash, Vulnerable older patients, Oncology, Colonic Neoplasms, FOLFIRI, Fluorouracil, Geriatrics and Gerontology, medicine.symptom, Colorectal Neoplasms, business, medicine.drug
Abstract

Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres. The median age was 75 (range, 70–85). Geriatric screening by G8 tool gave a score ≤ 14 in all patients. In total, 75 and 43 patients received FOLFOX or FOLFIRI, respectively, in combination with panitumumab (53%) or cetuximab (47%). The overall incidence of grade (G) 3–4 neutropenia was 11.8%, and for skin rash 11%. The most frequent adverse events were G1–2 skin rash (49.1%), G1–2 diarrhea (21.1%) and G1–2 nausea (17.7%). The ORR was 57.3%. Stable disease was observed in 29.1% of patients, with a disease control rate of 86.4%. With a median follow-up of 18 months, the median PFS was 10.0 months (95% confidence interval [CI]: 8.5–11.4), while the median OS was 18.0 months (95% CI: 16.0–19.9). No statistically significant difference was observed between the regimens in terms of ORR, PFS (p = 0.908), and OS (p = 0.832). Conclusion This study shows that with an appropriate design, including reduced doses, vulnerable older patients best tolerate chemotherapy when combined with anti-EGFR antibodies.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results